Our clinical trials will evaluate the efficacy of prioritised repurposed drugs as promising disease-modifying treatments for Parkinson’s disease. These drugs have been shortlisted by the Cure Parkinson’s Trust Linked Clinical Trials (LCT) program and have been rigorously evaluated for their potential to slow or halt the progression of the disease.